Skip to main content

Table 2 Selection of source and study populations

From: Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases

Inclusion/exclusion criteria n (%)
Source Population  
 GHP members aged ≥18 years who received myelosuppressive chemotherapy from 01/01/04 - 4/30/10 3823 (100.0)
  plus continuous health benefits during 60-day pretreatment period 3660 (95.7)
  plus ≥2 claims with primary cancer diagnosis beginning 60 days prior to chemotherapy initiation 3193 (83.5)
Study Population  
  plus admission to acute care, short stay hospital during chemotherapy course 772 (20.2)
  plus admitted to hospital within GHS 373 (9.8)
  plus ANC data available within 1 day of hospital admission 357 (9.3)
  1. GHP: Geisinger Health Plan; GHS: Geisinger Health System; ANC: absolute neutrophil count.